SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001636050-20-000009
Filing Date
2020-02-10
Accepted
2020-02-10 06:04:15
Documents
57
Period of Report
2019-12-31

Document Format Files

Seq Description Document Type Size
1 10-Q a12311910qaxovant.htm 10-Q 1347230
2 EXHIBIT 31.1 a123119exhibit311.htm EX-31.1 10121
3 EXHIBIT 31.2 a123119exhibit312.htm EX-31.2 10170
4 EXHIBIT 32.1 a123119exhibit321.htm EX-32.1 6215
5 EXHIBIT 32.2 a123119exhibit322.htm EX-32.2 6198
12 alpd.jpg GRAPHIC 30264
  Complete submission text file 0001636050-20-000009.txt   4420172

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT axon-20191231.xml EX-101.INS 516910
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT axon-20191231.xsd EX-101.SCH 38594
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT axon-20191231_cal.xml EX-101.CAL 56755
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT axon-20191231_def.xml EX-101.DEF 181933
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT axon-20191231_lab.xml EX-101.LAB 477190
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT axon-20191231_pre.xml EX-101.PRE 285016
Mailing Address 11 TIMES SQUARE 33RD FLOOR NEW YORK NY 10036
Business Address 11-12 ST. JAMES'S SQUARE SUITE 1, 3RD FLOOR LONDON X0 SW1Y 4LB 44 203 318 9708
Axovant Gene Therapies Ltd. (Filer) CIK: 0001636050 (see all company filings)

IRS No.: 981333697 | Fiscal Year End: 0331
Type: 10-Q | Act: 34 | File No.: 001-37418 | Film No.: 20589211
SIC: 2834 Pharmaceutical Preparations